

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Modified PTO Form 1449

Docket No. 395/35	Serial No. 09/510,562	HOH H	0
Inventor(s) Gerard M. HOUSEY		CENTER	0 13
Filing Date	Group	33	4 /
February 22, 2000	1636	<u> </u>	2002

## **U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*

<sup>\* -</sup> If pertinent

## FOREIGN PATENT DOCUMENTS

EXAMINER	DOCUMENT	DATE	COLINITRY	CLASS	CLIDCLASS	TRANSLATION	
INITIAL	NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO

## OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
N		Tagliaferri, P., Yanagihara, K., Ciardiello, F., Talbot, N., Flatow, U., Benade, L., Bassin, R.H. (1987) Effects of ouabain on NIH/3T3 cells transformed with retroviral oncogenes and on human tumor cell lines. Int. J. Cancer 40:653-8.
de		Umezawa, H., Imoto, M., Sawa, T., Isshiki, K., Matsuda, N., Uchida, T., Iinuma, H., Hamada, M., Takeuchi, T. (1986) Studies on a new epidermal growth factor-receptor kinase inhibitor, erbstatin, produced by MH435-hF3. J. Antibiot. (Tokyo) 39:170-3.

EXAMINER	DATE CONSIDERED			
Hand Jugo	11/2/02			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				
The second secon				

09/510,562